牛心包生物主动脉瓣的耐久性与临床经验
单中心1241例SAVR使用Trifecta瓣膜,中位年龄73.5岁,EuroSCORE 7.8,30天死亡率6.0%,8年全因死亡率自由率78.4%,再手术自由率93.3%。
要点
- Trifecta瓣膜8年再手术自由率93.3%,耐久性良好
- 30例SVD中17例V-in-V TAVI,13例外科取出
- 出院时中度PPM 5.5%,无重度PPM
核心结论
- Trifecta瓣膜SAVR长期耐久性优良,SVD可行V-in-V TAVI治疗
研究设计与样本
- 单中心回顾性队列,1241例SAVR患者,中位随访4.7年,总5469患者年
主要发现
- 30天死亡率6.0%,8年全因死亡自由率78.4%,瓣膜相关死亡自由率98.0%
- 8年再手术自由率93.3%,心内膜炎自由率96.5%
- 30例SVD中17例V-in-V TAVI,13例外科取出
关键数值与推荐
- 出院时中度PPM 5.5%,无重度PPM
- 术后并发症:心律失常44.7%,呼吸衰竭22.9%,急性肾衰需临时RRT 12.9%,低心排3.3%
临床怎么用
- Trifecta瓣膜可用于中高危SAVR患者,SVD后优先考虑V-in-V TAVI
局限性
- 单中心回顾性设计,外科风险较高(中位EuroSCORE 7.8)
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the implant experience and long-term outcomes from a large tertiary care referral center on surgical aortic valve replacement (SAVR) with a contemporary stented pericardial bioprosthesis with anticalcification treatment. METHODS: Patients underwent SAVR using the Trifecta valve at a single institution. Endpoints included procedural outcomes, adverse events, prosthesis-patient mismatch (PPM), long-term survival, and valve durability. Follow-up included 30-day, 6-month, and annual assessments. Treatment for structural valve deterioration (SVD) included surgical explant and valve-in-valve (V-in-V) transcatheter aortic valve implantation (TAVI). RESULTS: SAVR was performed in 1241 patients (median age, 73.5 ± 6.4 years; 54% male; median logistic EuroSCORE, 7.8) with concomitant procedures in 713 cases (57.5%). Intraprocedural mortality was 1.4%, and 30-day mortality was 6.0%. At hospital discharge, 68 patients (5.5%) had moderate PPM, and no patients had severe PPM. Adverse events included cardiac arrhythmias (44.7%, mostly atrial fibrillation), respiratory failure (22.9%), acute renal failure requiring temporary renal replacement therapy (12.9%), and low cardiac output syndrome (3.3%). Follow-up data were available over a total of 5469 patient-years (median duration of follow-up, 4.7 years). Freedom at 8 years from all-cause mortality, valve-related mortality, reoperation for SVD (redo SAVR or V-in-V TAVI), and endocarditis were 78.4%, 98.0%, 93.3%, and 96.5%, respectively. Of the 30 patients with SVD, 17 were treated by V-in-V TAVI and 13 underwent surgical explant. CONCLUSIONS: Outcomes from this large single-center cohort at increased surgical risk demonstrate excellent long-term durability of the Trifecta valve for SAVR and feasibility of treating SVD by V-in-V TAVI.
引用
- Lehmann S, Jawad K, Dieterlen MT, et al. Durability and clinical experience using a bovine pericardial prosthetic aortic valve. J Thorac Cardiovasc Surg. 2019. PMID: 31932059. doi:10.1016/j.jtcvs.2019.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。